ASBP
NASDAQAspire Biopharma Holdings Inc.
Price$7.37-1.30 (-14.99%)
12:30 PM08:30 PM
News · 26 weeks62-55%
2025-12-142026-06-07
Mix3090d
- SEC Filings16(53%)
- Market11(37%)
- Other3(10%)
Latest news
25 items- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Other Events8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- NEWSAspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 RevenueAdds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systemsAcquisition significantly accelerates Aspire's revenue, earnings growth and cash flow profileStrategically diversifies Aspire's revenue streamsOpportunity to drive significant shareholder value creation and enhance long-term capital allocation optionalityCompany does not anticipate procuring new equity financing to consummate the transaction ESTERO, FL / ACCESS Newswire / June 12, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced the signing of a definitive Share Purchase Agreement ("SPA") for the acquisition of 100%
- NEWSAspire Biopharma Issues Shareholder LetterESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson.Dear Fellow Shareholders,2026 is shaping up to be a defining year for Aspire Biopharma Holdings. We are moving with speed to transform our clinical pipeline into commercial reality, broadening the market reach of our high growth consumer segment, while simultaneously diversifying our business through a proposed strategic acquisition.Capital Market MilestonesOur Board of Directors recentl
- NEWSAspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of MembersESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.® (HVLP) gym chain with more than 225 locations open or on the way nationwide. Through the EoS Flex Deals affiliate program, BUZZ BOMB™ 's lineup of 50mg sublingual caffeine stick packs will now be available to an expansive community of health-conscious gym members. The EoS Flex Deals affiliate program is a premier partnerships platform designed to connect members with brands aligned with the EoS mission. With over 80 million impr
- SECSEC Form 10-Q filed by Aspire Biopharma Holdings Inc.10-Q - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECSEC Form SCHEDULE 13G filed by Aspire Biopharma Holdings Inc.SCHEDULE 13G - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)
- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aspire Biopharma Holdings Inc.SCHEDULE 13G/A - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)
- SECSEC Form DEFR14A filed by Aspire Biopharma Holdings Inc.DEFR14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECSEC Form DEF 14A filed by Aspire Biopharma Holdings Inc.DEF 14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- NEWSAspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split RatioESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".The reverse split is primarily intended to
- SECSEC Form PRE 14A filed by Aspire Biopharma Holdings Inc.PRE 14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- NEWSAspire Biopharma Announces $5.0 Million Share Repurchase ProgramESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors (the "Board") has authorized the repurchase of up to $5.0 million of the Company's common stock. The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS)."Aspire's strengthened financial position prov
- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- NEWSAspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS AcquisitionCompany secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase ESTERO, FL / ACCESS Newswire / April 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that it has closed the second and final tranche of the private placement announced on February 11, 2026 (the "Offering") for the purchase and sale of 26,250 shares of Series A Convertible Preferred Stock.Pursuant to the closing of the second and final tranc
- NEWSAspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon ExpoElite Ultra-Marathoner targets her second World Record in two months following historicUltra Jackpot 100 Win ESTERO, FL / ACCESS Newswire / April 17, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned subsidiary, Buzz Bomb Caffeine Company, is proud to announce that elite ultra-marathoner and BUZZ BOMB™ Global Brand Ambassador Ashley Paulson will attempt to shatter the female world record for the fastest 100-mile treadmill run.The historic attempt will take place live at the Boston Marathon Expo at the John B. Hynes Veterans Memorial Convention Center on Saturday, April 18, 2026. This Expo is held in conjunction with the Boston Marathon. Paulson a
- SECAmendment: Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K/A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- NEWSAspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 RevenueESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered into a Letter of Intent (LOI) to acquire Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. Management of DCS will be bolstered by the addition of a team from Lakewood & Company with more than 100 years' collective experience within the automotive industry.The proposed acquisition represents a transformative milestone for Aspire and position
- NEWSAspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail ExpansionInterwest to Drive Regional Growth for BUZZ BOMB™ Across Major Grocery and Convenience ChannelsESTERO, FL / ACCESS Newswire / April 15, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP) ("Aspire" or the "Company") wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a strategic sales and marketing brokerage agreement with Interwest Brokerage ("Interwest"). This partnership is designed to scale BUZZ BOMB™'s retail footprint across the grocery, convenience, and alternate channel sectors throughout the Intermountain West.Headquartered in Salt Lake City, Interwest is a premier independent Consumer Packaged Goods (CPG) solutions provider known for its high-impact retail execu
- SECAspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
- SECSEC Form EFFECT filed by Aspire Biopharma Holdings Inc.EFFECT - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
ASBP FAQ
5 questionsWhere does ASBP stock trade?
Aspire Biopharma Holdings Inc. (ASBP) is listed on NASDAQ.What sector and industry is ASBP in?
Aspire Biopharma Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aspire Biopharma Holdings Inc. go public?
Aspire Biopharma Holdings Inc. (ASBP) completed its IPO in 2022.What companies are similar to ASBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ASBP side-by-side with any of them on Quantisnow.How can I track ASBP on Quantisnow?
Quantisnow aggregates Aspire Biopharma Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASBP to receive live email and push alerts on every new disclosure.